Novavax COVID-19 vaccine, adjuvanted – Booster dose emergency use authorization
October 19, 2022 - Novavax announced the FDA has granted emergency use authorization (EUA) of Novavax’s COVID-19 vaccine, adjuvanted, to provide a first booster dose to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Novavax COVID-19 vaccine because they would otherwise not receive a booster dose of a COVID-19 vaccine.
Top